

Roham T Zamanian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2746307/publications.pdf>

Version: 2024-02-01

125
papers

5,578
citations

66234

42
h-index

88477

70
g-index

129
all docs

129
docs citations

129
times ranked

6054
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. <i>Chest</i> , 2022, 161, 1060-1072.	0.4	16
2	The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension. <i>Chest</i> , 2022, 161, 1347-1359.	0.4	9
3	Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1459-1468.	1.5	13
4	Insulin Growth Factor Phenotypes in Heart Failure With Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 935-946.	0.7	2
5	Peripheral Blood Inflammation Profile of Patients with Pulmonary Arterial Hypertension Using the High-Throughput Olink Proteomics Platform. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 66, 580-581.	1.4	2
6	Endogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1019-1034.	2.5	10
7	Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension. <i>Chest</i> , 2021, 159, 1586-1597.	0.4	13
8	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. <i>European Respiratory Journal</i> , 2021, 57, 2000414.	3.1	24
9	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. <i>Annals of the American Thoracic Society</i> , 2021, 18, 613-622.	1.5	27
10	Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension. <i>Scientific Reports</i> , 2021, 11, 12012.	1.6	12
11	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 209-221.	2.5	88
12	No Good Deed Goes Unpunished. <i>Chest</i> , 2021, 159, 910-911.	0.4	0
13	Pulmonary Arterial Hypertension Secondary to Drugs and Toxins. <i>Clinics in Chest Medicine</i> , 2021, 42, 19-38.	0.8	6
14	NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2040-2052.	1.2	13
15	Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. <i>Chest</i> , 2021, 160, 1442-1458.	0.4	17
16	Optimal Tricuspid Regurgitation Velocity to Screen for Pulmonary Hypertension in Tertiary Referral Centers. <i>Chest</i> , 2021, 160, 2209-2219.	0.4	5
17	Reply to Andr�asson et al.: Multiple Manifestations of Systemic Sclerosis Affect Walk Distance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 377-378.	2.5	4
18	Improving Right Ventricular Function by Increasing BMP Signaling with FK506. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 65, 272-287.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Targeted proteomics of right heart adaptation to pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002428.	3.1	16
20	FUNCTIONAL CLASS AND PHYSICIAN-PERCEIVED SEVERITY ARE SIMILAR IN TREATED AND UNTREATED PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: A REAL-WORLD SURVEY. <i>Chest</i> , 2021, 160, A2258-A2260.	0.4	0
21	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-7.	0.8	24
22	Prescription Patterns for Pulmonary Vasodilators in the Treatment of Pulmonary Hypertension Associated With Chronic Lung Diseases: Insights From a Clinician Survey. <i>Frontiers in Medicine</i> , 2021, 8, 764815.	1.2	1
23	Myocardial bridge: an unrecognized cause of chest pain in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-4.	0.8	0
24	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 148-157.	2.5	53
25	Hemodynamic trajectories and outcomes in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 204589402094134.	0.8	4
26	A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1576-1582.	1.5	47
27	PENet—a scalable deep-learning model for automated diagnosis of pulmonary embolism using volumetric CT imaging. <i>Npj Digital Medicine</i> , 2020, 3, 61.	5.7	72
28	Quantifying the Influence of Wedge Pressure, Age, and Heart Rate on the Systolic Thresholds for Detection of Pulmonary Hypertension. <i>Journal of the American Heart Association</i> , 2020, 9, e016265.	1.6	4
29	Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 130-132.	2.5	56
30	Anatomic, genetic and functional properties of the retinal circulation in pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-4.	0.8	5
31	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 945-953.	0.3	15
32	Mural Cell SDF1 Signaling Is Associated with the Pathogenesis of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 62, 747-759.	1.4	29
33	Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1407-1415.	2.5	18
34	Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. <i>Pulmonary Circulation</i> , 2020, 10, 1-7.	0.8	50
35	Multimodal fusion with deep neural networks for leveraging CT imaging and electronic health record: a case-study in pulmonary embolism detection. <i>Scientific Reports</i> , 2020, 10, 22147.	1.6	83
36	Abstract 14250: Semi-automated Analysis of Tricuspid Regurgitation Doppler Profile for Detection and Evaluation of Pulmonary Hypertension. <i>Circulation</i> , 2020, 142, .	1.6	0

#	ARTICLE	IF	CITATIONS
37	Development and Performance of the Pulmonary Embolism Result Forecast Model (PERFORM) for Computed Tomography Clinical Decision Support. <i>JAMA Network Open</i> , 2019, 2, e198719.	2.8	50
38	Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. <i>Circulation</i> , 2019, 140, 1409-1425.	1.6	54
39	Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2019, 124, 904-919.	2.0	141
40	Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011. <i>ERJ Open Research</i> , 2019, 5, 00017-2019.	1.1	7
41	Echocardiographic evaluations of right ventriculoarterial coupling in experimental and clinical pulmonary hypertension. <i>Physiological Reports</i> , 2019, 7, e14322.	0.7	14
42	Low-grade albuminuria in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 204589401882456.	0.8	11
43	Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 891-902.	2.5	69
44	Clinical trial design and new therapies for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801908.	3.1	142
45	H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1638-1641.	2.5	11
46	Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension. <i>European Journal of Immunology</i> , 2018, 48, 874-884.	1.6	31
47	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 166-174.	2.5	17
48	The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. <i>Pulmonary Circulation</i> , 2018, 8, 1-11.	0.8	30
49	Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	0.8	10
50	Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 388-391.	2.5	29
51	Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 788-800.	2.5	81
52	Methamphetamine and the risk of pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 416-424.	1.2	28
53	Reply: Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?. <i>International Journal of Cardiology</i> , 2018, 264, 188.	0.8	0
54	Noninvasive right ventricular load adaptability indices in patients with scleroderma-associated pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-11.	0.8	22

#	ARTICLE	IF	CITATIONS
55	Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire. <i>Chest</i> , 2018, 154, 848-861.	0.4	41
56	The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2018, 5, 217.	1.2	61
57	Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 314, L967-L983.	1.3	32
58	Prevention of Deep Vein Thrombosis and Pulmonary Embolism in High-Risk Medical Patients. <i>Clinics in Chest Medicine</i> , 2018, 39, 483-492.	0.8	9
59	Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension. <i>Molecular Genetics & Genomic Medicine</i> , 2018, 6, 835-844.	0.6	3
60	Stimulants and Pulmonary Arterial Hypertension: An Update. <i>Advances in Pulmonary Hypertension</i> , 2018, 17, 49-54.	0.1	4
61	Investigating the value of right heart echocardiographic metrics for detection of pulmonary hypertension in patients with advanced lung disease. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 825-835.	0.7	13
62	Identification of Pulmonary Hypertension Caused by Left-Sided Heart Disease (World Health) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 152, 792-799.	0.4	17
63	Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 313, L252-L266.	1.3	35
64	Leukotriene B ₄ antagonist ameliorates experimental lymphedema. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	112
65	Load Adaptability in Patients With Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2017, 120, 874-882.	0.7	15
66	Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	72
67	Left Atrium Maximal Axial Cross-Sectional Area is a Specific Computed Tomographic Imaging Biomarker of World Health Organization Group 2 Pulmonary Hypertension. <i>Journal of Thoracic Imaging</i> , 2017, 32, 121-126.	0.8	21
68	Whatâ€™s in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2017, 240, 386-391.	0.8	6
69	Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, e32-e47.	2.5	36
70	Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1602449.	3.1	119
71	Upregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 136, 1920-1935.	1.6	44
72	Differential expression of hepatocyte growth factor in patients with systemic sclerosis-associated pulmonary arterial hypertension. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 225-230.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database. PLoS ONE, 2017, 12, e0187734.	1.1	21
74	Psychometric Validation of the PAH Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results From the SYMPHONY Study. Chest, 2016, 150, 1160A.	0.4	0
75	Addressing the Controversy of Estimating Pulmonary Arterial Pressure by Echocardiography. Journal of the American Society of Echocardiography, 2016, 29, 93-102.	1.2	111
76	Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation, 2016, 133, 1240-1248.	1.6	289
77	Prognostic Utility of Right Atrial Emptying Fractions in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 473-480.	0.8	10
78	Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging, 2015, 8, 627-638.	2.3	44
79	RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 356-366.	2.5	66
80	Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 254-257.	2.5	104
81	Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1273-1286.	2.5	125
82	Single- vs Double-Lung Transplantation in Patients With Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis Since the Implementation of Lung Allocation Based on Medical Need. JAMA - Journal of the American Medical Association, 2015, 313, 936.	3.8	128
83	Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1102-1110.	2.5	138
84	Leukotriene B ₄ Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension. Hypertension, 2015, 66, 1227-1239.	1.3	62
85	Optical Coherence Tomography of Pulmonary Arterial Walls in Humans and Pigs (<i>Sus scrofa</i>) Tj ETQq1 1 0.784314 ggBT /Overlock 10 0.4 2		
86	Whole-Exome Sequencing Reveals <i>TOPBP1</i> as a Novel Gene in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1260-1272.	2.5	70
87	Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry. Chest, 2014, 146, 1494-1504.	0.4	121
88	Septal Curvature Is Marker of Hemodynamic, Anatomical, and Electromechanical Ventricular Interdependence in Patients with Pulmonary Arterial Hypertension. Echocardiography, 2014, 31, 699-707.	0.3	58
89	Response to Letter Regarding Article, "Transplantation for Idiopathic Pulmonary Arterial Hypertension: Improvement in the Lung Allocation Score Era". Circulation, 2014, 129, e458.	1.6	1
90	Relationship between Echocardiographic and Magnetic Resonance Derived Measures of Right Ventricular Size and Function in Patients with Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2014, 27, 405-412.	1.2	46

#	ARTICLE	IF	CITATIONS
91	Current Clinical Management of Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2014, 115, 131-147.	2.0	55
92	Impact of insulin resistance on ventricular function in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 721-726.	0.3	23
93	Erythropoietin Upregulation in Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2014, 4, 269-279.	0.8	18
94	Repurposing FK506 to Increase BMPR2 Signaling and Improve Pulmonary Arterial Hypertension: A Fast Track From Cells to People. <i>Advances in Pulmonary Hypertension</i> , 2014, 13, 129-133.	0.1	0
95	Transplantation for Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 2503-2513.	1.6	64
96	Pulmonary Arterial Hypertension: New Insights Into the Optimal Role of Current and Emerging Prostacyclin Therapies. <i>American Journal of Cardiology</i> , 2013, 111, 1A-16A.	0.7	62
97	Circulating Angiogenic Modulatory Factors Predict Survival and Functional Class in Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 369-380.	0.8	56
98	A Case of Recurrent Pericardial Constriction Presenting with Severe Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 436-439.	0.8	4
99	Blocking Macrophage Leukotriene B ₄ Prevents Endothelial Injury and Reverses Pulmonary Hypertension. <i>Science Translational Medicine</i> , 2013, 5, 200ra117.	5.8	203
100	Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry. <i>Chest</i> , 2013, 144, 160-168.	0.4	87
101	Diagnosis and Management of Pulmonary Hypertension Associated with Left Ventricular Diastolic Dysfunction. <i>Pulmonary Circulation</i> , 2012, 2, 163-169.	0.8	23
102	The Intersection of Genes and Environment. <i>Chest</i> , 2012, 141, 1598-1600.	0.4	15
103	Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2012, 110, 1546-1550.	0.7	34
104	Incidence, Correlates, and Consequences of Acute Kidney Injury in Patients With Pulmonary Arterial Hypertension Hospitalized With Acute Right-Side Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 533-539.	0.7	44
105	Characteristics and Outcomes of Pulmonary Hypertension in a Public County Hospital. <i>Chest</i> , 2011, 140, 733A.	0.4	0
106	Survival in Pulmonary Hypertension Registries: Response. <i>Chest</i> , 2011, 139, 1548-1549.	0.4	3
107	Pulmonary Hypertension Associated With Left Heart Disease: Characteristics, Emerging Concepts, and Treatment Strategies. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 154-167.	1.6	72
108	Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension. <i>Journal of Molecular Medicine</i> , 2011, 89, 971-983.	1.7	43

#	ARTICLE	IF	CITATIONS
109	Characteristics and Outcome After Hospitalization for Acute Right Heart Failure in Patients With Pulmonary Arterial Hypertension. <i>Circulation: Heart Failure</i> , 2011, 4, 692-699.	1.6	112
110	Disruption of the Apelin-APJ System Worsens Hypoxia-Induced Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 814-820.	1.1	148
111	Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL. <i>Chest</i> , 2010, 138, 1383-1394.	0.4	375
112	Right Ventricular Failure: A Novel Era of Targeted Therapy. <i>Current Heart Failure Reports</i> , 2010, 7, 202-211.	1.3	25
113	Worldwide Physician Education and Training in Pulmonary Hypertension. <i>Chest</i> , 2010, 137, 85S-94S.	0.4	26
114	Epoprostenol-associated pneumonitis: Diagnostic use of a T-cell proliferation assay. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 1071-1075.	0.3	6
115	PPAR β Activation: A Potential Treatment For Pulmonary Hypertension. <i>Science Translational Medicine</i> , 2009, 1, 12ps14.	5.8	68
116	ERG evaluation of daily, high-dose sildenafil usage. <i>Documenta Ophthalmologica</i> , 2009, 118, 225-231.	1.0	26
117	Angina Associated With Left Main Coronary Artery Compression in Pulmonary Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 527-530.	0.3	32
118	Plasma levels of S100A4 in portopulmonary hypertension. <i>Biomarkers</i> , 2009, 14, 156-160.	0.9	8
119	A Novel Non-Invasive Method of Estimating Pulmonary Vascular Resistance in Patients With Pulmonary Arterial Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2009, 22, 523-529.	1.2	70
120	Progressive Dyspnea After CABG: Complication of Retained Epicardial Pacing Wires. <i>Annals of Thoracic Surgery</i> , 2008, 86, 1352-1354.	0.7	27
121	Surrogate and Combined End Points in Pulmonary Arterial Hypertension. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 617-622.	3.5	35
122	Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. <i>Current Opinion in Pulmonary Medicine</i> , 2008, 14, 422-426.	1.2	12
123	Expanded Use of PAH Medications. <i>Advances in Pulmonary Hypertension</i> , 2008, 7, 249-254.	0.1	0
124	Management strategies for patients with pulmonary hypertension in the intensive care unit*. <i>Critical Care Medicine</i> , 2007, 35, 2037-2050.	0.4	240
125	Surgical and Interventional Therapies for Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 417-428.	0.8	17